ScalfariANeuhausADegenhardtARiceGPMuraroPADaumerM. The natural history of multiple sclerosis: A geographically based study 10. Relapses and long-term disability. Brain2010; 133: 1914–1929.
2.
CharcotJM. Histology de la Sclerose en Plaque. Gaz Hop (Paris)1868; 41: 554–555, 557–558, 566.
3.
DeLucaGCWilliamsKEvangelouNEbersGCEsriMM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain2006; 129: 1507–1516.
4.
TrappBDNaveKA. Multiple sclerosis: an immune or neurodegenerative disorder?Annu Rev Neurosci2008; 31: 247–269.
5.
NoseworthyJHVandervoortMKHopkinsMEbersGC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology1989; 39: 977–981.
6.
IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical trial results from a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993; 43: 655–661.
7.
IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Colombia MS/MRI Analysis Group. Neurology1995; 45: 1277–1285.
8.
ColesAJWingMGMolyneuxPPaolilloADavieCMHaleG. Monoclonal antibody treatment exposes the mechanism underlying the clinical course of multiple sclerosis. Ann Neurol1999; 46: 296–304.
9.
KremenchutzkyMCottrellDRiceGHaderWBaskervilleJKoopmanW. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain1999; 122: 1941–1950.
10.
KremenchutzkyMRiceGPABaskervilleJWingerchuckDMEbersGC. The natural history of multiple sclerosis: A geographically based study 9. Observations on the progressive phase of the disease. Brain2006; 129: 584–594.
